{µ-N,N,N',N'-Tetra-kis[(diphenyl-phosphan-yl)meth-yl]benzene-1,4-diamine}-bis-[(2,2'-bipyrid-yl)copper(I)] bis-(tetra-fluoridoborate).

In the title compound, [Cu(2)(C(10)H(8)N(2))(2)(C(58)H(52)N(2)P(4))](BF(4))(2), the dinuclear cation lies on an inversion centre. The Cu(I) atom is coordinated by two N atoms from a 2,2'-bipyridine ligand and two P atoms from an N,N,N',N'-tetra-kis-[(diphenyl-phos-phan-yl)meth-yl]benzene-1,4-diamine ligand in a distorted tetra-hedral geometry. In the crystal, inter-molecular C-H⋯F hydrogen bonds link the ions into layers parallel to [[Formula: see text]01]. π-π inter-actions [centroid-centroid distance = 3.668 (4) Å] are also observed. One F atom of the anion is disordered over two orientations with a refined occupancy ratio of 0.675 (13):0.325 (13).

Synthesis and characterization of spherical 2-diazo-4,6-dinitrophenol (DDNP).

Spherical 2-diazo-4,6-dinitrophenol (DDNP) with good flowability and controlled bulk density (0.65-0.95 g/cm(3)) has been prepared at factory scale by the modified method using 4-methylphenol as crystal control ingredient. Results showed that the yield of product was increased by 5-10%, and the waste water was significantly decreased due to circulation use of waste water compared with traditional method. Synthesized spherical DDNP was characterized by IR, laser granularity measurement, SEM, HPLC and XRD. IR spectrum confirmed the structural features of spherical DDNP. The particle analysis revealed that the modified method could offer spherical DDNP with average particle size of 350 microm and high purity (>98.52%). The XRD peaks of spherical DDNP have similar diffraction angles as those of traditional DDNP. The DSC profile of spherical DDNP showed the exothermic decomposition in the temperature range of 161.2-188.5 degrees C. The product can be pressed at over 40MPa without dead pressed phenomenon, and the minimum detonating charge of spherical DDNP was measured to be about 0.15g. Furthermore, impact sensitivity test suggested that spherical DDNP is less sensitive than traditional DDNP.

Preventive effect of Qianggan-Rongxian Decoction on rat liver fibrosis.

AIM: To study the preventive effects of Qianggan-Rongxian Decoction on liver fibrosis induced by dimethylnitrosamine (DMN) in rats. METHODS: Male Wistar rats were randomly divided into hepatic fibrosis model group, control group and 3 treatment groups (12 rats in each group). Except for the normal control group, all the rats received 1% DMN (10 muL/kg body weight, i.p), 3 times a week for 4 wk. The rats in the 3 treatment groups including a high-dose DMN group (10 mL/kg), a medium-dose DMN group (7 mL/kg), and a low-dose DMN group (4 mL/kg) were daily gavaged with Qianggan-Rongxian Decoction, and the rats in the model and normal control groups were given saline vehicle. Enzyme-linked immunosorbent assay (ELISA) was used to determine the changes in serum hyaluronic acid (HA), laminin (LN), and type IV collagen levels. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured using routine laboratory methods. Pathologic changes, particularly fibrosis, were examined by hematoxylin and eosin (HE) and Sirius red staining. Hepatic stellate cells (HSC) were examined by transmission electron microscopy. RESULTS: Compared with the model control group, the serum levels of HA, LN, type IV collagen, ALT and AST were decreased markedly in the other groups after treatment with Qianggan-Rongxian Decoction, especially in the medium-dose DMN group (P < 0.05). Moreover, the area-density percentage of collagen fibrosis was lower in the Qianggan-Rongxian Decoction treatment groups than in the model group, and a more significant drop was observed in the medium-dose DMN group (P < 0.05). CONCLUSION: Qianggan-Rongxian Decoction can inhibit hepatic fibrosis due to chronic liver injury, delay the development of cirrhosis, and notably ameliorate liver function. It may be used as a safe and effective thera-peutic drug for patients with fibrosis.

[Epidemiologic study on the relationship between smoking and sleep apnea/hypopnea syndrome].

OBJECTIVE: To investigate how smoking was affecting the prevalence of sleep apnea/ hypopnea syndrome (SAHS) among adults aged over 30 years in Chengde city of Hebei province. METHODS: 1168 subjects, over 30 years of age were derived from a random sample from a community-based population in Shuangqiao district of Chengde city. All subjects responded to a questionnaire at their own houses regarding their habits of snoring and smoking. 1168 subjects (95.2%) answered the questions satisfactorily. RESULTS: (1) Among the smoking groups, the prevalence of snoring was 69.09%, higher than that in the nonsmoking groups 45.07% (P = 0.000). (2) In males, the smoking group had a higher prevalence (69.72%) of snoring than in the nonsmoking group (60.80%, P = 0.033). (3) Females in the smoking group had a higher prevalence of snoring (61.80%) than in the nonsmoking group (39.70%, P = 0.011). (4) The prevalence of snoring in males (60.80%) was significantly higher than that in females (39.70%, P = 0.000). (5) The prevalence (69.72%) of snoring in smoking males was similar to that in smoking females (61.80%, P = 0.336). (6) Data from logistic regression analysis indicated that smoking was one of the factors affecting snoring. (7) According to the degree of snoring, 127 moderate and severe snorers were measured by portable PSG for a whole night and the prevalence of SAHS was estimated. According to the AHI > or = 5 and the ESS > or = 9 cutoff-points, the prevalence rates of SAHS in smoking groups were both significantly higher than that in nonsmoking groups (P < 0.001). CONCLUSION: Smoking and snoring among adults aged over 30 years had correlation in our city.

Relationship between atrial natriuretic peptide-immunoreactive cells and microvessels in rat gastric mucosa.

AIM: To investigate the ultrastructural localization of atrial natriuretic peptide (ANP)-synthesizing cells and the relationship between ANP-synthesizing cells and microvessels in rat gastric mucosa. METHODS: Immunohistochemistry techniques and postembedding immunoelectron microscopy techniques were used to validate the findings regarding the expression of ANP-synthesizing cells and the ultrastructural localization of ANP-synthesizing cells in the gastric mucosa. Histochemistry techniques and the tannic acid-ferric chloride method (TA-Fe staining method) were used to reveal microvessel density and the distribution of ANP-synthesizing cells in different regions of the stomach. RESULTS: Cells expressing ANP were localized and ANP-synthesizing cells were identified as enterochromaffin (EC) cells in the gastric mucosa. ANP-synthesizing cells existed in different regions of the stomach. The percentage ANP-synthesizing cells in the mucosa was greatest in the fundus (46.7%+/-5.3%), intermediate in the antrum (40.1%+/-4.5%), and least in the body (21.6%+/-3.6%). There was a positive relationship between the percentage of ANP-synthesizing cells and the density of microvessels in the antral mucosa, but not in the fundus or body mucosa. CONCLUSION: ANP is synthesized by EC cells in rat gastric mucosa, and ANP-synthesizing cells are most dense in the gastric fundus. ANP may act not only as a regional autocrine and/or paracrine regulator, but also as an endocrine regulatory peptide in the gastrointestinal tract.